This is a special medicine used to treat certain kinds of skin cancer, like melanoma. It works by helping your body's own immune system fight the cancer cells more effectively. It's given as an injection.
Every report comes from a Lived member, sent anonymously.
Have you tried Yervoy (Ipilimumab) for Melanoma?
Ipilimumab, sold as Yervoy, is a cancer immunotherapy given by intravenous infusion. It belongs to a group of medicines called immune checkpoint inhibitors, which release a brake on the immune system so it can attack cancer more effectively. It was first approved for melanoma, the most serious common type of skin cancer, and melanoma is the only cancer for which it is used on its own. For adults and children 12 and older whose melanoma has spread or cannot be removed with surgery, it can be given alone or together with nivolumab (Opdivo), another checkpoint inhibitor. It is also approved on its own for adults after surgery for melanoma that had spread into nearby lymph nodes, to lower the chance of the cancer coming back. For other cancers, ipilimumab is used only with nivolumab, mostly as the first treatment for advanced disease. These include kidney cancer (renal cell carcinoma) with an intermediate or poor outlook; liver cancer (hepatocellular carcinoma), either as a first treatment or after sorafenib, an earlier liver cancer medicine; malignant pleural mesothelioma, a cancer of the lining around the lungs; squamous cell cancer of the esophagus; and non-small cell lung cancer whose tumor lacks EGFR or ALK gene changes (changes usually treated with targeted pills instead), sometimes with two cycles of chemotherapy. It is also used in adults and children 12 and older for colorectal cancer that has spread or cannot be removed and that tests show is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), meaning the tumor cells cannot properly fix errors made when DNA is copied. Several of these uses depend on tumor testing, such as the level of the PD-L1 protein for some lung and esophageal cancers.
T cells are immune cells that can recognize and destroy abnormal cells, including cancer cells. To keep immune responses from running out of control, T cells carry off switches called checkpoints. One of these is CTLA-4 (cytotoxic T-lymphocyte antigen 4), which holds T-cell activity back. Cancers can benefit from these brakes and avoid immune attack. Ipilimumab is a monoclonal antibody, a lab-made protein designed to attach to one specific target. It binds to CTLA-4 and blocks it, so more T cells become activated and multiply, including T cells inside the tumor. It may also weaken regulatory T cells, which normally keep immune responses in check. Nivolumab blocks a different checkpoint, PD-1, which is why the two medicines are often paired. The same release of the brakes explains the main drawback. A more active immune system can also attack healthy tissue, causing inflammation in organs such as the bowel, liver, skin or hormone glands. Because the drug works through the immune system rather than killing cancer cells directly, it helps some people a great deal and others not at all.
Ipilimumab is given in a hospital or infusion clinic as a drip into a vein (an intravenous, or IV, infusion), usually over 30 minutes. It is not a pill or a shot under the skin. The dose is based on body weight and on the cancer being treated. The schedule depends on the regimen. For advanced melanoma, and for several cancers treated with nivolumab, ipilimumab is typically given every 3 weeks for up to four doses, after which nivolumab often continues on its own. For lung cancer, mesothelioma and esophageal cancer, ipilimumab is given every 6 weeks alongside more frequent nivolumab, for up to 2 years. After melanoma surgery, it is given on its own every 3 weeks for four doses, then every 12 weeks for up to four more doses, so the full course lasts up to about a year. Blood tests before starting and before each dose check the liver, kidneys and hormone levels, including thyroid function. Doses are often delayed or stopped when side effects need treatment. If an appointment is missed, call the clinic soon to reschedule.
Tiredness, diarrhea, itching, rash, nausea and headache are the most common side effects of ipilimumab alone. With nivolumab, people also commonly have muscle and joint pain, fever, cough, poor appetite, shortness of breath and an underactive thyroid. Immune side effects happen more often with the combination than with ipilimumab alone. The serious risks come from the immune system attacking healthy organs. The bowel, liver, skin and hormone glands are most often involved, but the lungs, kidneys, eyes, nerves and heart can also be affected. These reactions can be severe or fatal, can begin at any point during treatment, and can also start after treatment ends. Most are treated with steroid medicines such as prednisone, often with ipilimumab paused or stopped, and getting treatment early helps keep them from becoming more serious. Contact the oncology team right away, including after hours, for any new or worsening symptom. Bowel inflammation can show as diarrhea or more frequent bowel movements, black, bloody or mucus-containing stools, or severe belly pain. Liver inflammation can cause yellowing of the skin or eyes, or dark urine. Skin reactions include a new rash, blistering or peeling skin, or painful mouth sores, and lung inflammation can cause a new or worsening cough, shortness of breath or chest pain. A headache that will not go away, vision changes, extreme tiredness, dizziness or fainting can signal inflammation of the pituitary gland at the base of the brain, or problems with the adrenal or thyroid glands. Less often, reduced urine can point to the kidneys, numbness, tingling or muscle weakness to the nerves, and an irregular heartbeat to the heart. Damage to these glands is often lasting, and many people who develop it need hormone replacement long term. Reactions to the infusion itself, such as chills, flushing, fever, wheezing or feeling faint, can happen during treatment. Tell the nurse right away if they start, so the infusion can be slowed or stopped.
No condition automatically rules out ipilimumab, but a person's immune history matters to the decision. Tell the cancer team about any autoimmune disease, such as ulcerative colitis, Crohn's disease or lupus; an organ transplant; a nerve condition such as myasthenia gravis or Guillain-Barré syndrome; or a past or planned stem cell transplant from a donor. People with active autoimmune disease were left out of the main trials, so the risks for them are less well understood. In people who have a donor stem cell transplant either before or after ipilimumab, serious and sometimes fatal complications can occur, including graft-versus-host disease, in which the donor's immune cells attack the body. Ipilimumab can harm a developing baby. A pregnancy test is done before starting, and anyone who could become pregnant should use effective birth control during treatment and for 3 months after the last dose. Breastfeeding is not recommended during treatment or for 3 months afterward. The team should also know about all other prescriptions, over-the-counter medicines, vitamins and herbal supplements.
Treatment usually means a visit every few weeks for blood tests, a symptom check and the infusion. On most combination schedules the ipilimumab doses are limited, but nivolumab and monitoring continue afterward. Scans at intervals show whether the cancer is shrinking, stable or growing. Results vary widely. Some people get little or no benefit, while others have long-lasting control of the cancer. In a large melanoma trial with at least 10 years of follow-up, people who started on nivolumab plus ipilimumab lived a median of about 6 years (half lived longer and half shorter), compared with about 3 years on nivolumab alone and under 2 years on ipilimumab alone. Among people whose melanoma had not grown 3 years after starting the combination, about 96% had not died of melanoma 10 years later. Results in other cancers differ, so the expected benefit is best discussed for the specific diagnosis and stage. Because immune side effects can appear after the last dose, new symptoms still deserve a call to the oncology team for months after treatment ends.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Yervoy (Ipilimumab), what you've noticed, or ask the community a question.